Previous 10 | Next 10 |
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade - - Topline efficacy and biomarker data for both monotherapy and combination arms of dose escal...
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will present at the following confe...
- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in specific tumor types - - Multiple clinical milestones expected in 2024 - - Strong balance sheet with cash runway extended into the fourth quart...
Sensei Biotherapeutics Inc. (SNSE) is expected to report $-0.28 for Q3 2023
2023-11-07 08:29:18 ET More on Sensei Biotherapeutics Seeking Alpha’s Quant Rating on Sensei Biotherapeutics Historical earnings data for Sensei Biotherapeutics Financial information for Sensei Biotherapeutics For further details see: Sensei Biothe...
- SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported - - Phase 1/2 trial of SNS-101 continues to enroll ahead of schedule, with new...
2023-11-06 10:03:02 ET DENVER, Colo., Nov. 6, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; OrganiGram Holdings Inc (NASDAQ: OGI), British American Tobacco PLC (NYSE: BTI), Sensei Biotherapeutics Inc (N...
2023-11-06 09:32:11 ET DENVER, Colo., Nov 6, 2023 ( www.247marketnews.com )- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) presented, after Friday’s market close, initial monotherapy dose-escalation portion data from its Phase 1/2 clinical trial for SNS-101, a conditionally active,...
- Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile across multiple dose cohorts - - First VISTA-blocking antibody administered at a dose anticipated to be therap...
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Busin...
News, Short Squeeze, Breakout and More Instantly...
Sensei Biotherapeutics Inc. Company Name:
SNSE Stock Symbol:
NASDAQ Market:
Sensei Biotherapeutics Inc. Website:
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 428.5% to $0.983 on volume of 924,758,481 shares Greenwave Technology Solutions Inc. (GWAV) fell 4.2% to $0.0849 on volume of 393,457,542 shares Netcapital Inc. (NCPL) rose 10.1% to $0.1925 on volum...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 5.3% to $0.0839 on volume of 148,968,464 shares Netcapital Inc. (NCPL) rose 66.0% to $0.2901 on volume of 111,713,040 shares Cue Health Inc. (HLTH) rose 33.6% to $0.126 on volume of 99,7...
- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET - BOSTON, May 23, 2024 (GLOBE NEW...